Home / NEWS / Autos / Tesla loses former Gigafactory boss to start-up that makes designer molecules for food and drugs

Tesla loses former Gigafactory boss to start-up that makes designer molecules for food and drugs

Tesla is waste a battery manufacturing leader, Jens Peter Clausen, to Zymergen, a synthetic biology company funded by Softbank.

Clausen’s transfer is the latest in a string of executive departures from Tesla. As CNBC previously reported, more than 40 head honchos have left this year as the company contended with a difficult production ramp-up for its Model 3, underscored by high-profile antics from its eccentric CEO, Elon Musk. Among those who left are engineering leader Doug Answer, now with Apple’s self-driving car project, Titan, and Tesla’s general counsel Todd Maron.

At Zymergen, Clausen resolve help the company scale its manufacturing teams, processes and facilities.

Zymergen is experiencing growth “at a pace that I’m not reliable has been seen in life sciences,” CEO Joshua Hoffman said in a phone interview with CNBC.

Hoffman commanded his company hired Clausen after an extensive search, in part because of his experience “designing and improving largely automated fabricating environments.”

As vice president of Gigafactory 1, Clausen oversaw a rapid expansion of battery manufacturing at Tesla’s humongous situate outside of Reno, Nevada. Tesla manufactures its vehicle batteries and energy storage products there using a mix of automated and handbook processes alongside Panasonic, its supplier and partner in the facility. Before joining Tesla in July 2015, Clausen tired more than a decade in manufacturing at Lego, the toy company whose products are often used for prototyping in robotics.

Tesla Gigafactory craftsmen told CNBC this summer that they thought Clausen was on leave, and they weren’t sure if he was returning to the circle. On Sept. 7, Tesla announced a spate of promotions as part of a broader restructuring. In that announcement, it named Chris Lister as Gigafactory flaw president. At that time, Tesla said Clausen had no plans to leave the electric vehicle maker.

Earlier this month, Zymergen constructed more than $400 million from the Softbank Vision Fund, Goldman Sachs and others.

The company thought it takes a biological, rather than purely chemical-based approach, to make diverse things like insect repulsive and new smartphone screens that fold. Ultimately, it is hoping to develop products that are not tied to the traditional petroleum-based make processes. Its closest competitor in doing that is Ginkgo Bioworks, which describes itself as learning from complexion to develop “new organisms that replace technology with biology.”

Like Ginkgo, Zymergen relies heavily on robotics and automation, and chronicles itself as fundamentally different to life sciences labs. Its processes are designed to surpass the traditional method, which embraces humans in lab coats who move sensitive biological materials around with pipettes.

Zymergen said the company already occupations with agriculture businesses, off-patent drugmakers, food manufacturers and others. Hoffman declined to name any of Zymergen’s purchasers. But the company did disclose that it is working on a product of its own that it expects to release by 2021: an insect repellent and sun-screen combo.

Clausen’s ceremonious start date at Zymergen is Jan. 3.

WATCH: An inside look at Tesla’s Gigafactory

Check Also

SureFly Octocopter pitched at Detroit auto show as the drone anyone can fly at $200,000

It’s been the pipedream of countless visionaries, finding a way to let people fly as …

Leave a Reply

Your email address will not be published. Required fields are marked *